Searching for "eye" found 15

Italy Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European ophthalmic markets, breaking into orphan drugs and adding value in the glaucoma field—and is now seeing its ambitions become a…

Thailand Thailand boasts one of the most attractive business and investment environments in the ASEAN region, and pharmaceutical companies implanted in the country benefit from a highly-skilled workforce and enabling infrastructure. Despite some areas in which the country can improve, as well as a degree of political uncertainty, experts still have…

Turkey Seizing the cost competitiveness of the Turkish market and the government’s nurturing of local manufacturing, Turkish companies are looking to harness their geographic positioning and export to developed and developing markets alike.   We did not shy away from entering the most advanced healthcare ecosystems. Barış Özyurtlu, General Manageger, Berko Ilac.…

UK Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and establishing standards of care on a European level.   I see technology as the enabler that creates new possibilities. Imaging…

China Dr. Harley Seyedin, president of AmCham South China, talks up increasing connectivity in the region, competition and collaboration between the Greater Bay Area cities, and their potential for international life sciences investors. Harley, you have been in the South China region as an extremely successful businessman for nearly three decades.…

Innovation The new AI tech from Google’s DeepMind can diagnose over 50 retinal diseases with more accuracy than your optometrist. Research conducted by Nature Medicine found that a ground-breaking artificial intelligence system developed by Moorfields eye hospital, University College London and Google’s DeepMind can identify over 50 eye diseases with 94% accuracy. Among the diseases…

Colombia The executive director of the AmCham Colombia shares his insights on the legacy of strong economic ties between the two countries. He speaks about the changing socio-political landscape of Colombia, the role of American companies in the pharmaceutical sector, as well as the attractive factors that makes Colombia “The New…

Switzerland Dr. Andrea Michael Meyer, general manager of Sanofi Genzyme Switzerland, reveals how the Swiss business has been experiencing year-on-year double-digit growth; how rare diseases was the foundation of Sanofi Genzyme´s business and remains a key part of their DNA; and how a focus on patient centricity remains at the core…

Switzerland Michael Cobas Meyer of Eli Lilly Switzerland reveals how these are very exciting times for the company, particularly given an extremely rich pipeline in the areas of diabetes, oncology and bio-medicines; how the challenge will be to transition from their existing portfolio to new products; and why Lilly´s focus is…

Mexico José Reyes Baeza Terrazas, general director of ISSSTE (Institute for Social Security and Services for State Workers) documents some of the institution’s key specificities that make it one of the most complete social security organizations in all Latin America, while he reveals his strategic priorities to ensure ISSSTE becomes a…

biotech The founder of this spin-off of the Autonomous University of the State of Morelos focusing on biologicals for human and veterinary use offers an overview of how the company came into life, the lack of culture at Mexican universities of filing patents for academic research and the potential of the…

Generics Earl Stanley Perez, General Manager of Meyerf Philippines, explains the importance of focusing on a few niches to succeed in a growing in a competitive market such as the Philippines, stressing the need for local companies to raise brand awareness and not only target the private sector but partner with…